Deaconess Clinic Inc

1. Eli Lilly and Company $536,736 32 payments
2. Genentech, Inc. $523,713 41 payments
3. Allergan Inc. $494,121 62 payments
4. AbbVie, Inc. $343,865 102 payments
5. Pfizer Inc. $163,382 59 payments
6. Kowa Research Institute, Inc. $160,763 32 payments
7. VIVUS, Inc. $158,140 15 payments
8. Amgen Inc. $113,828 8 payments
9. Aimmune Therapeutics, Inc. $98,034 33 payments
10. Teva Pharmaceuticals USA, Inc. $76,474 36 payments

1. Roche Cancer Screening Collection Study $523,713 41 payments
2. A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $250,051 4 payments
3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $209,883 14 payments
4. A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents $158,140 15 payments
5. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $139,096 54 payments
6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $126,594 14 payments
7. K-877-302 $105,303 17 payments
8. A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study $98,034 33 payments
9. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $89,363 21 payments
10. Pediatric Options for Migraine Relief A Randomized, Double Blind, Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $89,175 10 payments

1. Other $159,973 16 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.